Vanguard Capital Management
PHIO icon

Vanguard Capital Management’s Phio Pharmaceuticals PHIO Stock Holding History

Vanguard Capital Management’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.6K Buy
94,262
+14,409
+18% +$16.4K ﹤0.01% 3881
2026
Q1 		$97.4K Buy
+79,853
New +$91.1K ﹤0.01% 3867

Other funds holding PHIO

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Capital Management's PHIO Position: Q2 2026 in Review

Vanguard Capital Management increased its Phio Pharmaceuticals (PHIO) stake by 18% in Q2 2026, buying an estimated $16.4K and bringing the position to 94,262 shares worth $96.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3881.

Vanguard Capital Management first reported a position in PHIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $97.4K in Q1 2026. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

  • Vanguard Capital Management held 94,262 shares of Phio Pharmaceuticals worth $96.6K as of Q2 2026.
  • Vanguard Capital Management bought 14,409 Phio Pharmaceuticals shares in Q2 2026, an estimated $16.4K.
  • Phio Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3881 holding.
  • Vanguard Capital Management first reported a position in Phio Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Phio Pharmaceuticals position peaked at $97.4K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.